1. Home
  2. CERO vs CNSP Comparison

CERO vs CNSP Comparison

Compare CERO & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • CNSP
  • Stock Information
  • Founded
  • CERO 2017
  • CNSP 2017
  • Country
  • CERO United States
  • CNSP United States
  • Employees
  • CERO N/A
  • CNSP N/A
  • Industry
  • CERO
  • CNSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • CERO
  • CNSP Health Care
  • Exchange
  • CERO Nasdaq
  • CNSP Nasdaq
  • Market Cap
  • CERO 8.4M
  • CNSP 6.5M
  • IPO Year
  • CERO N/A
  • CNSP 2019
  • Fundamental
  • Price
  • CERO $1.84
  • CNSP $0.14
  • Analyst Decision
  • CERO
  • CNSP Strong Buy
  • Analyst Count
  • CERO 0
  • CNSP 1
  • Target Price
  • CERO N/A
  • CNSP $0.50
  • AVG Volume (30 Days)
  • CERO 742.5K
  • CNSP 13.3M
  • Earning Date
  • CERO 02-24-2025
  • CNSP 03-31-2025
  • Dividend Yield
  • CERO N/A
  • CNSP N/A
  • EPS Growth
  • CERO N/A
  • CNSP N/A
  • EPS
  • CERO N/A
  • CNSP N/A
  • Revenue
  • CERO N/A
  • CNSP N/A
  • Revenue This Year
  • CERO N/A
  • CNSP N/A
  • Revenue Next Year
  • CERO N/A
  • CNSP N/A
  • P/E Ratio
  • CERO N/A
  • CNSP N/A
  • Revenue Growth
  • CERO N/A
  • CNSP N/A
  • 52 Week Low
  • CERO $1.70
  • CNSP $0.08
  • 52 Week High
  • CERO $1,238.00
  • CNSP $23.90
  • Technical
  • Relative Strength Index (RSI)
  • CERO 33.43
  • CNSP 77.89
  • Support Level
  • CERO $1.70
  • CNSP $0.09
  • Resistance Level
  • CERO $2.22
  • CNSP $0.12
  • Average True Range (ATR)
  • CERO 0.28
  • CNSP 0.01
  • MACD
  • CERO 0.25
  • CNSP 0.01
  • Stochastic Oscillator
  • CERO 9.46
  • CNSP 79.91

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Share on Social Networks: